Breast Cancer Clinical Trials in San Antonio, TX

Breast Cancer Clinical Trials in San Antonio, TX

View the best 10 breast cancer medical studies in San Antonio, Texas. Access promising new therapies by applying to a San Antonio-based Breast Cancer clinical trial.

Trials in San Antonio, Texas

Here are the top 10 medical studies for breast cancer in San Antonio, Texas

Image of Pacific Cancer Care ( Site 0142) in Monterey, United States.

Pembrolizumab +1 More

Immune Checkpoint Inhibitor

Recruiting1 awardPhase 2
This trial is comparing the efficacy of two different treatments for triple negative breast cancer - olaparib plus pembrolizumab versus chemotherapy plus pembrolizumab. The primary hypotheses are that olaparib plus pembrolizumab will be superior to chemotherapy plus pembrolizumab in terms of progression-free survival and overall survival.
Image of M D Anderson Cancer Center in Houston, United States.

Hypofractionated Radiation Therapy +1 More

Radiation Therapy

Recruiting1 awardPhase 2
This trial is comparing two different treatment schedules for women who need radiation therapy to their lymph nodes as part of their breast cancer treatment. One schedule takes 6 weeks and the other takes 4 weeks. The purpose of the trial is to see if the shorter schedule will lower the risk of developing arm swelling, also known as lymphedema, after radiation treatment.
Image of Baptist MD Anderson Cancer Center in Jacksonville, United States.

Partial Breast Irradiation

Radiation

Recruiting1 awardPhase 2 & 3
This trial looks at how well a shorter, higher-dose radiation therapy works to treat early stage breast cancer. The cancer is only in the breast, and this treatment may have fewer side effects.
Image of New York Cancers & Blood Specialists in Port Jefferson Station, United States.

SV-BR-1-GM +1 More

Virus Therapy

Recruiting2 awardsPhase 3
This trial evaluates a new treatment for advanced breast cancer with no other alternatives available.
Image of University of Alabama at Birmingham in Birmingham, United States.

Gedatolisib +2 More

PI3K/mTOR Inhibitor

Recruiting2 awardsPhase 3
This trial is testing a combination of drugs to treat advanced breast cancer that has not responded to other treatments. The drugs work by blocking growth signals, breaking down estrogen receptors, and stopping cell division. Tamoxifen is a commonly used drug that blocks estrogen receptors to treat breast cancer, but resistance to it often develops.
Image of Highlands Oncology Group Main in Fayetteville, United States.

Trastuzumab

Recruiting1 awardPhase 3
This trial tested a combination of drugs for patients with advanced breast cancer that has a specific genetic mutation. The goal was to see if this combination could better control the cancer by blocking growth signals. The study was stopped due to changes in treatment approaches, not because of safety issues.
Image of Northwestern Medicine Cancer Center in Warrenville, United States.

TOL2506

Hormone Therapy

Recruiting2 awardsPhase 3
This trial tests TOL2506, a treatment that stops ovaries from working, in premenopausal women and men with hormone-sensitive breast cancer. It aims to reduce hormone levels to slow down or stop cancer growth. TOL2506 is a treatment that stops ovaries from working, similar to other ovarian suppression methods.
Image of Kaiser Permanente - Oakland in Oakland, United States.

Letrozole +2 More

Hormone Therapy

Recruiting1 awardPhase 3
This trial will compare two treatments for breast cancer: giredestrant with palbociclib, and letrozole with palbociclib. The trial will measure how well the treatments work and how safe they are.
Image of Research Site in Scottsdale, United States.

Trastuzumab Deruxtecan

Monoclonal Antibodies

Recruiting2 awardsPhase 3
This trial is testing a new drug called trastuzumab deruxtecan for patients with advanced breast cancer that hasn't responded to other treatments. The drug works by specifically targeting and killing cancer cells. The study aims to see if this drug helps patients live longer or improves their quality of life compared to other treatments. Trastuzumab deruxtecan has shown significant clinical benefits in treating advanced breast cancer and other similar tumors.
Image of Los Angeles County-USC Medical Center in Los Angeles, United States.

Ceralasertib +1 More

Enzyme Inhibitor

Recruiting1 awardPhase 1
This trial will find the best dose and safety of ceralasertib when given with trastuzumab deruxtecan to treat patients with solid tumors that have a change in the HER2 gene or protein.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.